RX108 / Suzhou NeuPharma - LARVOL DELTA

Cardiac Glycosides Toxicity: Mechanisms and Mitigation Strategies in Recent Studies. (PubMed, Chem Biol Interact) - "Although their antitumor potential, exemplified by derivatives such as RX108 entering clinical trials, has renewed research interest, inherent cardiotoxicity remains a major safety concern...In addition, we examine their multi-organ toxicity profiles and corresponding clinical management strategies, with particular emphasis on digoxin-specific Fab antibodies. Another pivotal aspect of this review is a critical analysis of contemporary, rational structural modification strategies designed to decouple cardiotoxicity from therapeutic efficacy. By synthesizing these insights, this work aims to provide a foundational framework for overcoming the toxicity hurdles and advancing the repurposing of cardiac glycosides in precision oncology and other therapeutic areas."

Journal • Review • Cardiovascular • Oncology

Phase I study to evaluate Safety and Tolerability of RX108-A Tablets in Patients with advanced Cancer (ANZCTR) - P1 | N=20 | Recruiting | Sponsor: NeuPharma Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Trial initiation date • Oncology • Solid Tumor

Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma. (PubMed, Mol Cancer Ther) - "Taken together, these findings reveal a novel approach to target glutamine metabolism through inhibiting Na+/K+-ATPase and provide a rationale for using RX108 to treat HCC in patients whose tumors express ASCT2 at high levels. RX108 is currently under clinical development."

Journal • CNS Disorders • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Psychiatry • Solid Tumor • SLC1A5

A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: NeuPharma, Inc. | Trial completion date: Dec 2021 ➔ Dec 2023 | Trial primary completion date: Aug 2021 ➔ Aug 2023

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: NeuPharma, Inc.; Trial completion date: Sep 2020 ➔ Dec 2021; Trial primary completion date: Mar 2020 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor